Dyne Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Dyne Therapeutics's estimated annual revenue is currently $17.5M per year.
- Dyne Therapeutics's estimated revenue per employee is $119,150
- Dyne Therapeutics's total funding is $333M.
- Dyne Therapeutics's current valuation is $478.7M. (January 2022)
Employee Data
- Dyne Therapeutics has 147 Employees.
- Dyne Therapeutics grew their employee count by 34% last year.
Dyne Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | President & CEO | Reveal Email/Phone |
3 | VP, Head Translational Biomarkers | Reveal Email/Phone |
4 | VP, Head Biometrics | Reveal Email/Phone |
5 | VP - Head Platform Development | Reveal Email/Phone |
6 | VP, Head Technology | Reveal Email/Phone |
7 | SVP, Pharmacovigilance | Reveal Email/Phone |
8 | VP, Program Team Leader and Head New Product Planning | Reveal Email/Phone |
9 | VP, Global Head Patient Advocacy and Engagement | Reveal Email/Phone |
10 | SVP, Program Team Leader and Head Program Management and Operations | Reveal Email/Phone |
Dyne Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Dyne Therapeutics?
Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.
keywords:N/A$333M
Total Funding
147
Number of Employees
$17.5M
Revenue (est)
34%
Employee Growth %
$478.7M
Valuation
N/A
Accelerator
Dyne Therapeutics News
Reviewing Dyne Therapeutics (NASDAQ:DYN) and Sol-Gel Technologies (NASDAQ:SLGL). Posted by admin on Apr 23rd, 2022.
Dyne Therapeutics posted earnings per share of ($0.50) in the same quarter last year, which suggests a negative year over year growth rate of 76...
Analysts predict that Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) will post ($0.88) earnings per share (EPS) for the current quarter,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $18.9M | 147 | 23% | $137.5M |
#2 | $28.7M | 148 | -10% | $227M |
#3 | $28.9M | 149 | 18% | $125.4M |
#4 | $34.4M | 149 | 0% | N/A |
#5 | $23.9M | 150 | 8% | N/A |